#Zhichuang Tongqiao (02190.HK) Initiation Coverage: Dual Neurovascular + Peripheral Platform Enters Profit Realization Phase, Yet Valuation Still Prices in "Zero Growth"
Rating: Cautiously Bullish Target Price: HKD 26.1–29.6 (base-case fair value range, 12–18 months) Current Price: HKD 20.50 (close, 2026-10-09) Margin of Safety: approx. +27% (versus base-case fair range floor of HKD 26.1) Time Horizon: 12–18 months | Report Date: 2026-10-10 | Currency: HKD (financials in RMB)
Liquidity note: The company's average daily turnover is approximately 0.08%–0.15% of market cap, hovering near the 0.1% conventional warning threshold. Institutional-scale capital flows face significant impact costs; this report's valuation conclusions already incorporate a liquidity discount, but we caution that such discount may persist long term.
Zhichuang Tongqiao is the only domestic vascular intervention device platform company simultaneously covering both neurovascular intervention and peripheral vascular intervention lines. In 2026H1, revenue was RMB 632 million (+31.1%), adjusted net profit RMB 189 million (+43.7%), and gross margin 73.4%, a record high since listing; operating cash flow covered net profit approximately 1.0–1.3x; net cash on hand was approximately RMB 1.978 billion, about 34% of market cap. The current price of HKD 20.50 corresponds to approximately 14.8–16.0x expected adjusted P/E for 2026 (this report's forecast basis and the sell-side consensus basis), below MicroPort NeuroTech, whose growth has stalled (approx. 22.4x), and Xinwei Medical, with only about 40% of its scale (approx. 20.8x, both on a TTM basis). Our core judgment: the market disagrees little about profitability itself—the disagreement is over the multiple. The current price effectively prices in "zero growth after 2026," while both of the company's product lines remain on a 20%–40% growth trajectory. The key to valuation repair is the mild landing of centralized procurement renewals and full-year earnings delivery; the biggest risk is the expansion of national centralized procurement for high-value consumables into neurovascular stent categories. We assign a Cautiously Bullish rating with a target price of HKD 26.1–29.6, corresponding to 15–17x 2027E adjusted P/E in the base scenario.
What kind of return this is: Approximately 70% comes from valuation multiple repair (current 14.8–16.0x 2026E → base case 15–17x 2027E), and about 30% from earnings delivery above expectations (this report's 2026E adjusted net profit of RMB 380–400 million, about 6%–11% above the sell-side consensus of approx. RMB 360 million).
Primary stock price driver: The volume-price rebalancing of centralized procurement for high-value consumables—the fourth procurement-year renewal for coils (peak period 2026Q4–2027Q1) and the execution effect of peripheral drug-coated balloons (DCB) in the sixth national procurement batch since May 2026—are the most intensive pricing variables over the next two quarters.
Demonstrable expectation gap: The current price of HKD 20.5 corresponds to a market cap of approx. RMB 5.77 billion; after deducting net cash, enterprise value is approx. RMB 3.79 billion. Back-solving with this report's normalized free cash flow of approx. RMB 310 million and a 9.5%–11.5% discount rate range implies a perpetual growth rate after 2026 of roughly 0%–3%—meaning the market is paying almost nothing for the company's 30%+ revenue growth. The sell-side consensus target price of HKD 31.2 (5 Buy, 0 Sell, retrieved 2026-10-10) is about 52% above the current price, including CICC (2026-08-24, DCF: WACC 11.4%, perpetual growth 2.2%) with a target of HKD 32. The disagreement lies not in earnings forecasts but in the pricing of HK small-cap liquidity discounts and centralized procurement tail risks.
Validation and falsification: Validation catalysts—profit alert window around January 2027, annual results in March 2027, approval of the liquid embolic agent, continued buybacks. Falsification conditions—neurovascular stent categories entering the eighth national procurement batch, coil renewal price cuts substantially exceeding the 10%–15% precedent, or full-year 2026 adjusted net profit below the RMB 360 million consensus. The expectation gap is driven by "event validation" rather than simply waiting for capital inflows—this is the core pillar of this opportunity's viability. Conversely, if the peripheral line's growth stalls in 2026H2 after national procurement prices take effect, the thesis would be equally quickly falsified.
Revenue grew from RMB 528 million in 2023 to RMB 1.057 billion in 2025 (CAGR approx. 41.6%), continuing +31.1% in 2026H1; gross margin rose rather than fell over the three years of procurement expansion (71.6% → 72.1% → 73.4%), attributed by management to manufacturing improvements, supply chain optimization, and automation-driven yield gains, plus a higher mix of new products. Operating cash flow quality: 2026H1 operating net cash was RMB 233 million, including RMB 38.66 million of interest received—coverage of net profit was approx. 1.26x including interest and approx. 1.0x excluding interest, both in healthy territory. Two constraints must be stated explicitly: first, the growth staircase is decelerating (revenue growth 48.3% → 35.1% → 31.1%; neuro line approx. +20% in 2026H1), and growth will most likely fall below 25% in 2027; second, 2026H1 trade receivables rose from RMB 8.38 million to RMB 38.83 million (+363%), growing significantly faster than revenue—an early signal of lengthening collection cycles post-procurement, to be reviewed in the annual report (see the "Financial Engineering and Cross-Period Consistency" section).
On a unified basis the conclusion should be more cautious: on a TTM basis this company trades at a 12%–22% discount to peers (rather than the 30%–40% suggested by cross-basis comparison). On a 2026E basis, this report's forecast (adjusted net profit RMB 390 million) implies 14.8x, and the sell-side consensus (RMB 360 million) 16.0x, with a PEG of approx. 0.6–0.7. Reverse DCF is highly sensitive to terminal assumptions—CICC derives HKD 32 with WACC 11.4% and perpetual growth 2.2%—so "implied zero growth" should be understood as a directional signal that "the current price pays nothing for growth," not a precise measure. Sell-side coverage is only 5 houses, all Buy-rated (mostly initiations after November 2025); the consensus target price carries optimistic self-selection and serves only as a reference anchor, not fair value. Overall: the undervaluation judgment holds but the magnitude converges to a modest range; repair depends on catalyst delivery, and low liquidity means the discount may persist.
The opposing facts must also be stated: the peripheral drug-coated balloon has entered the sixth national procurement batch (bidding January 2026); the company's UltraFree DCB was selected in Group A, with selected price range approx. RMB 1,677–6,015, implemented in various regions from May 2026—yet the DCB is precisely the #1 growth driver of the peripheral line (+40% in 2026H1), and all of 2026H1's volume-price data were generated before national procurement prices took effect; the second half is the first real test of volume compensating for price at national procurement price levels. On the neurovascular side, exclusion from the seventh batch does not mean exclusion from the eighth: national procurement is expanding on an "include wherever possible" pace (six batches covering 9 major categories and 142 product types), and the remaining neurovascular categories are widely recognized by the market as a candidate pool; since December 2025 Beijing has already included coils/intracranial stents/flow diverters in hospital-group procurement. Historical resilience provides a buffer: in FY2024, despite centralized procurement plus preemptive price cuts, gross margin fell only 1.3 percentage points. The nature of this thesis is "risk budgeting" rather than "positive confirmation"—we adopt a base assumption of a further 15%–25% procurement renewal cut offset by 30%–50% volume growth, and designate "renewal cuts exceeding 25% or stent categories entering the national procurement list" as falsification lines.
The full picture of shareholder returns: first dividend in FY2024 (RMB 0.10 per share), raised to RMB 0.22 in FY2025; buyback amounts rising year by year (approx. HKD 25.05 million in 2023 → approx. HKD 130 million in 2025); no share placements after IPO. Three discounts must be honestly noted: first, cumulative 2026 buybacks of approx. HKD 110 million represent only approx. 1.7% of market cap; dividends plus buybacks total a shareholder return yield of approx. 3%—the "floor" magnitude is limited and is closer to a signal; second, repurchased shares are all held as treasury shares (14.128 million shares at end-September) for incentive plan delivery, while exercisable options under the 2025/2024 incentive plans total approx. 18.03 million shares, exceeding current treasury holdings—buybacks currently outpace incentive share outflows (net reduction of approx. 2.88 million shares in H1), but if options are exercised in concentration, net share count reduction is unsustainable; third, buybacks coexist with the option pool stockpiling function, and their pace is not necessarily driven purely by valuation judgment. The balance sheet itself is a harder protection: net cash of RMB 1.978 billion can easily cover the redemption liability for the remaining 40% stake in Optimed due in 2028 (present value approx. RMB 268 million).
Judging the magnitude of the second curve: the peripheral line's revenue share has risen from approx. 32% in FY2024 to 39.1% in 2026H1; of overseas revenue, Optimed contributed approx. RMB 40.6 million on consolidation and the organic portion approx. RMB 30 million (organic growth approx. +91%, driven by a mix of low base and the revenue recognition basis change from Germany's switch to direct sales). Three constraints: the Optimed German entity's annualized loss of approx. RMB 64 million (approx. 16% of 2026E net profit) must converge through the French transition and supply chain synergies, or goodwill impairment risk rises; the core pipeline has a record of systematic delays (liquid embolic slipping, drug-eluting stent yet to deliver), and the 2026H1 R&D spend of -12.5% (clinical trial costs RMB 53.9 million → 34.5 million) corroborates the pipeline delays—management must explain the internal consistency between shrinking investment and pipeline delivery; and the peripheral flagship product, the DCB, has entered national procurement execution (see C3). Net judgment: the second-curve direction holds, and the peripheral line's three-year +50.3%/+40.0% slope is real, but its net contribution to 2026–2027 profit should be "significant on revenue, neutral-to-positive on profit"—it should not be priced on linear extrapolation.
| Metric (RMB) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue (RMB 100mn) | 5.28 | 7.82 | 10.57 | 6.32 |
| Revenue YoY | — | +48.3% | +35.1% | +31.1% |
| Gross margin | 72.9% | 71.6% | 72.1% | 73.4% |
| Net profit attributable to shareholders (RMB 100mn) | -0.79 | 1.00 | 2.44 | 1.82 |
| Adjusted net profit (Non-IFRS, RMB 100mn) | 0.07 | 1.24 | 2.73 | 1.89 |
| Net margin (GAAP) | -14.9% | 12.8% | 23.1% | 28.3% |
| R&D expenses (RMB 100mn) | 2.61 | 2.33 | 2.47 | 1.06 |
| Selling expenses (RMB 100mn) | 1.64 | 1.75 | 1.95 | 1.15 |
| Operating cash flow (RMB 100mn, company basis) | — | 1.27 | 3.21 | 1.94 (ex-interest) / 2.33 (incl. interest) |
| Capex (RMB 100mn) | 1.91 | 1.91 | 1.11 | 0.33 |
| Cash + wealth management (RMB 100mn, period end) | 25.77 | 25.10 | 26.00 | 23.89 (2026-06-30) |
| Interest-bearing debt (RMB 100mn, period end, excl. redemption liability) | 0.50 | 0.87 | 0.60 | 1.11 |
| Liabilities/assets ratio | — | — | — | approx. 19.7% (2026-06-30, calculated) |
Note: Adjusted net profit is the company's Non-IFRS basis (only adding back share-based compensation, SBC: FY2025 add-back RMB 28.7 million, 2026H1 add-back RMB 9.7 million); net cash is RMB 1.978 billion (= 23.89 − 1.11 − 2.68 redemption liability − 0.32 leases, 2026-06-30). The company has no net debt; the net debt/EBITDA metric is not applicable.
Reasons for metric changes (items with YoY ≥ ±20%, management explanations): ① Overseas revenue +349.3%: volume ramp in Europe, Latin America, and Asia + consolidation of Optimed in April 2026 (interim results announcement / Note 31); ② Peripheral revenue +40.0%: new product volume growth + Optimed consolidation; ③ R&D expenses -12.5%: "testing, clinical trial and R&D professional service fees decreased from RMB 53.9 million to RMB 34.5 million," plus improved R&D project management mechanisms (management's words); ④ Income tax 0 → RMB 24.92 million: a subsidiary has exhausted accumulated tax losses and begun paying taxes (HNTE 15% rate + R&D super deduction); ⑤ Net finance income -38.8%: lower bank interest income + new interest on the Optimed redemption liability; ⑥ Borrowings +85.6%: due to the Optimed acquisition; ⑦ Trade receivables RMB 8.3 million → 35.6 million (+327%): no specific attribution from the company (MD&A only vaguely cites tightened credit policies)—a key focus of this report; ⑧ Inventories +35.8%: includes RMB 56.1 million from Optimed consolidation, attributed by management to higher commercialization penetration.
2026H1 revenue was RMB 632 million (+31.1%), of which neurovascular was RMB 366 million (+20.2%, 57.9% share), peripheral intervention approx. RMB 247 million (+40.0%, 39.1% share), and others (Optimed urology, etc.) RMB 19 million (3.0% share); overseas revenue was RMB 71 million (+349.3%, 11.2% share, of which Optimed contributed approx. RMB 41 million). Adjusted net profit was RMB 189 million (+43.7%), with an adjusted net margin of 29.9% (prior-year period 27.3%); GAAP net profit attributable to shareholders was RMB 182 million (+49.9%). Three operating highlights: gross margin of 73.4% (+2.2pp), a post-listing high; selling expense ratio of 18.2% (prior-year period 17.7%, due to Optimed integration and international marketing investment); covered hospitals rose to 3,500+ (approx. 3,000 in FY2023), with 70 commercialized products in China. Two negative items: the R&D spending contraction of -12.5% YoY runs in parallel with pipeline delays; and income tax of RMB 24.92 million has begun to accrue, an effective tax rate of approx. 12.2%, with full-year tax burden set to consume about a quarter of profit growth. The stock rose approx. 7% the day after results, a positive market reaction; sell-side houses subsequently maintained Buy ratings with modest upward revisions—the "above expectations" judgment is benchmarked against the sell-side consensus (this report's 2026E net profit forecast is approx. 6%–11% above consensus, a modest beat rather than something entirely unpriced by the market).
Business model in brief: A high-value single-use interventional consumables platform — an asset-light manufacturing model of R&D + in-house production + distributor-led sales, with gross margin around 73%. Revenue has no subscription attribute; repurchases are driven by surgical volume. The company has no direct pricing power over end prices (set by centralized procurement/tender pricing), but competes on winning-bid share through its full-category registration certificate matrix and product quality — management states that "our reputation for high-quality products allows us to price slightly above domestic competitors."
Cash content of earnings: OCF/net profit — FY2024 ~1.27, FY2025 ~1.31 (company-defined operating cash/net profit), 2026H1 ~1.0 (excluding interest) to 1.26 (including interest); FCF/net profit — FY2024 was -0.64 (capex of RMB 191 million during capacity build-out exceeded operating cash), FY2025 turned positive at 0.86, 2026H1 reached 1.12. Capex/depreciation fell from 5.0x (Hangzhou/Zhuhai facility construction period) to 2.9x — the capacity investment peak has passed; the company does not disclose a maintenance vs. growth capex split. Conclusion: book profit has been covered by cash flow for two consecutive years; earnings quality has shifted from "interest-dependent" to "operations-driven" — net finance income fell from 65% of pre-tax profit in FY2024 to ~8% in 2026H1.
Recurring earnings review: The company's Non-IFRS adjustments only add back SBC — no aggressive items like restructuring/amortization/FX — a restrained definition. However, SBC is a recurring cost (RMB 28.7 million added back in FY2025, or 10.5% of adjusted net profit; 5.1% in 2026H1, with the share declining), and it is settled with treasury shares without incremental dilution. Under a "more conservative definition" excluding SBC, FY2025 adjusted net profit of RMB 273 million corresponds to a true shareholder-basis profit of ~RMB 244 million (i.e., GAAP net profit attributable to owners).
Return on capital: FY2025 NOPAT ~RMB 200 million — total invested capital ROIC is only ~6.1% (diluted by RMB 2.6 billion net cash), while operating invested capital ROIC is ~20.7% (excluding financial assets), significantly above WACC (9.5%–11.5%); after turning profitable in 2024, the company entered a value-creation zone. Annualized ROE ~12%, the highest among comparable peers (MicroPort NeuroTech ~10.5%, Heartflow ~7.6%).
Moat and quality warnings: Moat = full-category registrations (32 neuro + 38 peripheral products approved in China) enabling a "win all tenders + bundled supply" positioning, plus coverage of 3,500 hospitals. Three quality warnings: ① Trade receivables up 4.3x in six months with loss provisions amplified 65x (see E4); ② Optimed pro-forma annualized loss ~RMB 64 million plus RMB 154 million goodwill on the books; ③ After declining interest income, profit relies more on operations — the "hidden dividend" of falling rates has disappeared.
Consistency between words and deeds: pragmatic, slightly conservative. Delivered commitments: auxiliary embolization stent (Feilong) promised for 2025 → approved in Q4 2025, delivered; "keep R&D spending relatively stable" → FY2024 -10.6%, FY2025 +5.8%, absolute level stable at RMB 230–260 million, delivered; Optimed acquisition and integration commitment → closed in April 2026, transition of German distribution to direct sales completed within two months, delivered. Not delivered: liquid embolic agent described as "expected as early as 2026" in both FY2024 and FY2025 annual reports, but pushed back in the 2026 interim pipeline table — delayed within 6 months of going public; drug-eluting stent (2027) and OCT series (2027) remain to be verified. The company never issues revenue/profit guidance (no record of high-profile misses), and pipeline timelines show systematic delays, though all are accompanied by "may not ultimately be successfully developed and commercialized" disclaimers. Overall verdict: partially delivered, leaning pragmatic — operational commitments are highly credible; pipeline timelines should default to a 6–12 month haircut.
Shareholder friendliness: friendly. FY2024 first post-IPO dividend (RMB 0.10/share), raised to RMB 0.22 in FY2025 (payout ratio 30.4%); buyback amounts rising over three years (HK$25.05M → HK$46.99M → HK$130M), with near-daily buybacks from July–October 2026 at HK$20.5–21.9, overlapping the current price; zero placements or rights issues post-IPO, and incentives settled in treasury shares. Deductions: combined buyback/dividend yield ~3%, still modest in magnitude.
Risk signals: The Chairman and CEO roles are held by one person, Zhao Zhongyi (deviating from CG Code provision C.2.1; the board says it aids stability); the concert-party group shrank in April 2026 (Zhong Shengping and WEA exited); no pledges by the largest shareholder group (disclosed in each period 2024–2026); no record of controlling-shareholder selling. Governance blind spot to track: the company does not disclose top-five customer/distributor concentration.
| Segment | 2026H1 Revenue | Share | YoY | FY2025 YoY | Business logic in one line |
|---|---|---|---|---|---|
| Neurovascular intervention | RMB 366M | 57.9% | +20.2% | +28.0% | Full ischemic + hemorrhagic + access portfolio; the base business trading volume for price after centralized procurement |
| Peripheral vascular intervention | ~RMB 247M | 39.1% | +40.0% | +50.3% | DCB/venous stents/thrombectomy/radiofrequency closure — the fastest-growing first growth engine |
| Others (Optimed urology, etc.) | RMB 19M | 3.0% | First period of consolidation | — | European venous/urology; channel synergies, drags gross margin near-term |
| Of which: overseas (cross-line) | RMB 71M | 11.2% | +349.3% | +115.5% | Own registrations + Optimed direct sales — the second curve of international expansion |
The company reports only a single operating segment and does not disclose gross margin by product line — a genuine disclosure gap. Inferred profit driver: the neuro line, at 57.9% of revenue with the deepest historical accumulation, remains the profit base; the peripheral line, with higher growth, has become the main source of incremental profit (of the RMB 150 million revenue increment, 6.32 − 4.82, peripheral contributed ~RMB 71 million and neuro ~RMB 62 million). Gross margin structure: management disclosed that Optimed's product mix carries a lower gross margin that dilutes the overall figure, while the in-house neuro/peripheral lines have seen gross margins rise even under centralized procurement — the gross margin gap between the two is estimated at over 10 percentage points (due to the early stage of Europe's distribution-to-direct-sales transition plus the urology product mix; exact figure undisclosed). The company's core business is not a single-product one, and segment information suffices to support the "dual-engine" thesis, but SKU-level breakdown (thrombectomy stents/coils/flow diverters shares individually) is not disclosed, so centralized-procurement sensitivity can only be estimated at the product-line level.
Accounting red flags: ① Surge in trade receivables (severity: medium) — 2026H1 trade receivables of RMB 35.58 million (vs RMB 8.33 million at start of year, +327%), loss provisions jumping from RMB 50K to RMB 3.245 million (65x), and a new 3–6 month aging bucket of RMB 10.44 million; management's MD&A offered no specific attribution, contradicting the FY2025 annual report's statement of "tightening credit policy to accelerate receivables turnover." ② New intercompany/third-party loans (severity: low) — other receivables for the first time include employee advances of RMB 27.91 million and loans to third parties of RMB 10 million, with limited disclosure of their nature. ③ Volatile non-operating items (severity: low) — FY2024/FY2025 net other losses of RMB -43.6M/-46.8M (fair-value changes on Avinger preferred shares, increased donations), suppressing GAAP profit for two consecutive years without itemized quantification.
Cross-period consistency: ① Trade receivables as % of annualized revenue rose 0.2% → 1.1% → 2.8%, inconsistent with management's explanation (the inflection occurred in the same reporting period as Optimed consolidation; direct sales naturally carry longer receivable cycles, but the company does not split domestic vs. overseas); ② R&D expense ratio steadily declining 49.5% → 29.8% → 23.3% → 16.8%, consistent with management's explanation (more products reaching market + improved R&D management); ③ Interest income as % of pre-tax profit 65% → 23% → 8%, consistent with falling rates and cash shifting to wealth-management products. Overall: absolute levels are low (receivables still <3% of total revenue), but the directional signal is negative; year-end receivables aging and domestic/overseas splits are must-check items.
Current market data (close of 2026-10-09): Share price HK$20.50; shares outstanding 329.8 million (336.4M H shares + 7.8M domestic shares − 14.3M treasury shares), market cap ~HK$6.76 billion (~RMB 5.77 billion, at 1 RMB = 1.1727 HKD, as of 2026-10-10; ~HK$7.05 billion if computed on total share count including treasury shares). Certainty multiples: PE(TTM, GAAP) 19.26x (2nd percentile over 1 year, 1st percentile over 3 years — earnings are in a ramp-up phase; historical percentiles are polluted by the near-breakeven period, for reference only); PE(TTM, adjusted) 17.4x; PB 1.97x (26th percentile over 1 year; annualized ROE ~12%, highest among peers — PB must be read alongside ROE); PS(TTM) 4.78x.
| Peer comparison (2026-10-09) | Market cap (HK$100M) | PE-TTM | PB | FY2025 revenue growth | Annualized ROE | Key differentiator |
|---|---|---|---|---|---|---|
| Zhuhui medical (Executor Medical) | 67.6 | 17.4 (adj.)/19.3 (GAAP) | 1.97 | +35.1% | ~12% | Neuro + peripheral dual platform; consolidated profitability for two consecutive years |
| MicroPort NeuroTech | 45.8 | 22.4 | 2.30 | +3.8% | 10.5% | Hemorrhagic leader but growth stalled (net profit -27.4%); suspended from trading since 2026-09-01 |
| Heartflow Medical | 22.2 | 19.6–20.8 | 1.59 | +46.9% | 7.6% | Pure ischemic, small base, high growth; first full-year profit in 2025 |
| Peijia Medical | 31.3 | Loss-making | 1.48 | +15.8% | Negative | TAVR segment losses drag; neuro segment already profitable |
Market-implied expectations: Enterprise value net of cash ~RMB 3.79 billion; back-solving from normalized FCF of ~RMB 310 million at a 9.5%–11.5% discount rate, the current price implies a post-2026 perpetual growth rate of ~0%–3%. In one line: the current price assumes near-zero growth beyond 2026, while reality shows revenue +31%, adjusted net profit +44%, and sell-side consensus implying +52% upside. The disagreement is not over FY2026 earnings (consensus RMB 360M vs. this report's RMB 380–400M, a 6%–11% gap) but over the multiple — small-cap HK liquidity discount (average daily turnover ~0.08%–0.15% of market cap) + a tail-risk premium for centralized procurement. This discount is not entirely mispricing: low liquidity is structural, and repair requires incremental capital catalysts such as southbound inclusion, accelerated buybacks, or index events.
Three-tier value (EPV): Asset value tier — net cash ~HK$7.0/share (a conservative floor, 34% of the current price, excluding replacement value of operating assets); zero-growth EPV tier — normalizing FY2026E adjusted net profit of ~RMB 390M into NOPAT of ~RMB 327M + depreciation RMB 50M − capex RMB 66M − change in working capital of 0 yields normalized FCFF of ~RMB 311M (~HK$1.11/share); capitalized at WACC 9.5% and adding back net cash, EPV ~HK$18.7/share, ~91% of the current price (WACC 9%–10% gives a range of HK$18.1–19.3); growth option tier — the residual of current price minus EPV is ~HK$1.8/share, ~9% of the current price. Interpretation: the market is currently paying almost only for "zero-growth going concern + full cash," leaving the peripheral second engine, overseas +349%, Optimed synergies, and pipeline options essentially unpriced — this means the downside has two layers of protection (EPV + net cash), and upside comes from the "repricing of a 9% option," which depends on catalysts rather than time.
Three scenarios and odds (12–18 months):
| Scenario | Probability | Fair value range (HK$) | vs. current price | Decisive factors |
|---|---|---|---|---|
| Bear | 30% | 15.6–16.9 | -23.9%~-17.6% | Tender renewal price cut of 25%+ with volume growth stalling + competitive squeeze: FY2027E adjusted net profit falls to ~RMB 365M × 12–13x (bottom-range multiple for no-growth HK medical device companies; excludes the extreme tail of neuro stents entering national procurement) |
| Base | 50% | 26.1–29.6 | +27%~+44% | Moderate renewal (15%–25% price cut offset by 30%–50% volume growth) + peripheral/overseas delivery on trend: FY2027E adjusted net profit ~RMB 490M × 15–17x (anchor: one notch below the TTM 19.6–22.4x of two profitable peers to reflect liquidity discount; cross-checked by PEG 0.6–0.7) |
| Bull | 20% | 36.8–40.7 | +80%~+98% | Peripheral second engine + overseas outperformance + resonance from liquid embolic/drug-eluting stent approvals: FY2027E ~RMB 545M × 19–21x (re-rated to the center of high-growth device companies, referencing sell-side target prices implying 22.5x 2026E) |
Probability-weighted fair value ~HK$26.6 (~+30% vs. current price). The current price sits toward the lower end between the bear-case upper bound and the base-case lower bound; the odds are asymmetric: +36% to the base-case midpoint, -21% to the bear-case midpoint. Basis for the base-case exit multiple: one notch below the peer median (TTM ~20–22x) to reflect small-cap liquidity, and not anchored on the company's own current trading multiple (avoiding circularity); the bear-case multiple anchors the 10–14x historical bottom range for no-growth HK device companies. Tail note: if the 8th batch of national procurement includes neuro-interventional stents (an open risk emphasized by the red team; no catalog-level evidence yet), the impact could fall below this report's bear case (~HK$9–10 magnitude); we handle this tail with a 30% bear probability + catalog watchlist monitoring rather than widening the main scenario ranges.
In-house earnings forecast (reconciliation anchor): FY2026E revenue RMB 1.35–1.40 billion (+28%~+32%, H2/H1 seasonal factor 2.14–2.19 vs. FY2025 actual of 2.19), adjusted net profit RMB 380–400M (+39%~+46%); FY2027E revenue RMB 1.62–1.76 billion, adjusted net profit RMB 465–515M. Management gives no quantitative guidance (the company never issues numeric guidance); vs. sell-side consensus (FY2026E revenue ~RMB 1.47B / net profit ~RMB 360M): this report is more conservative on revenue and more optimistic on profit, with the gap in tax-rate and Optimed loss-narrowing assumptions. Biggest uncertainty: 2026H2 is the first concentrated execution period for DCB national procurement pricing, Beijing Class-III procurement, and Shenzhen flow-diverter price cuts — the H2 YoY +23% hurdle is not high, but policy concentration risk may be underestimated.
Conclusion: Undervalued, but of the "moderately undervalued + discount-persistence risk" type. Quality (dual-engine growth, 73% gross margin, net cash 34% of market cap, operating ROIC ~21%) and price (14.8–16.0x 2026E, EPV protection, net-cash floor) are scored separately: quality is excellent, and the price is cheap for structural reasons. Target price HK$26.1–29.6 = base-case fair value; margin of safety ~+27% (to the base-case lower bound).
Industry Size: China's neurointerventional device market (ex-factory price basis) — Frost & Sullivan (as cited in the company prospectus): approximately RMB 4.9 billion in 2019, projected at RMB 37.1 billion by 2030; Sullivan's updated 2023 estimate (as cited by Cailian Press): approximately RMB 6.0 billion in 2019, projected at RMB 48.9 billion by 2030; CIC (Ekos Medical prospectus / as cited by Huaan Securities): approximately RMB 10 billion currently, above RMB 40 billion by 2028 (CAGR ~36.5%, includes aggressive procedural penetration assumptions). Synthesizing the three sources, this report adopts a conservative-to-median estimate: approximately RMB 10 billion currently, with a 5-year CAGR of about 15%–25% (CIC's 36.5% serves as the upper-bound reference). By category: ischemic products ~RMB 9 billion in 2027E (2022–2027E CAGR ~31%); flow-diverters (FD) ~RMB 12.6 billion in 2027E (CAGR ~84%, aggressive estimate; actual pace depends on post-VBP volume ramp). Peripheral vascular intervention (China): ~170,000 peripheral arterial procedures in 2022, device market above RMB 5.3 billion; peripheral arterial stents + balloons ~RMB 6.8 billion in 2030E (Frost & Sullivan, as cited in Heartflow Medical's annual report); global peripheral intervention ~USD 9.6 billion in 2023 → ~USD 16.2 billion in 2030E (CAGR 7.5%), with China growing ~11%, faster than global (QYResearch). Underlying demand: stroke incidence rose from 4.56 million in 2017 to 5.17 million in 2021 (CAGR 3.2%), projected at ~7.24 million by 2032; ~84 million intracranial aneurysm patients (Frost & Sullivan white paper).
Penetration Rate Is the Core Volume Driver: China's stroke interventional treatment penetration rate is ~1.7% vs. ~11.8% in the US (CIC) — a 7x gap underpins the industry's long-term growth; VBP price cuts have unlocked grassroots accessibility (average price of thrombectomy stents dropped from RMB 26,900 to below ~RMB 4,000; flow-diverters from ~RMB 110,000 to ~RMB 60,000), while the pace of volume release depends on DSA installation and operator training (stroke prevention and treatment center construction, large-scale equipment renewal policies indirectly expanding the market).
Value Chain and Value Distribution: Upstream (nitinol/platinum-tungsten alloy wires, polymer extrusion and precision braiding, radiopaque markers — domestic substitution rate for premium access products below 5%, per Huaan Securities) has moderate bargaining power over scaled manufacturers; midstream device makers are the value core, with gross margins of 70%–75% pre-VBP (Zhongchuang 73.4%, MicroPort NeuroScience 73.5%, Shingwei 70.9%) — gross profit is largely retained in the midstream; after VBP compressed terminal prices to ex-factory levels, distribution was significantly squeezed (Henan neuro + peripheral alliance VBP cut hospital annual procurement from RMB 2.46 billion to RMB 1.15 billion, average reduction of 53.6%), distributors have been downgraded from "promotion" to "delivery," manufacturers bid directly, and downstream bargaining power has shifted to centralized healthcare procurement — this company's positioning is a full-category midstream player actively embracing VBP in exchange for share (subject to 10 VBP rounds in 2024; management claims to be "the first in the industry to actively embrace VBP").
Supply-Demand and Competitive Landscape: Foreign players (Medtronic, Stryker, J&J/MicroVention, BD, Terumo) once held over 90% of China's neurointerventional market; domestic share rose from under 10% to ~25% in 2023 and ~26% in 2024 (ByDrug/NBD, full-category basis); the number of approved products expanded rapidly from 2021 to 2024 (MicroPort NeuroScience 8→25, Zhongchuang 10→23, Shingwei 11→22), and the industry is in a phase of "supply ramp-up + elimination race" — declining VBP winning rates (only 20% in the 2023 Beijing-Tianjin-Hebei 3+N alliance) are driving share concentration toward leaders. Product-level landscape: FD flow-diverters — Medtronic ranked first in 2022, MicroPort NeuroScience's Tubridge second at ~44% (sell-side research, 2022 snapshot); coils — Zhongchuang's domestic share ~10% in 2023 (company annual report basis, as cited by ArteryNet); the four listed domestic players' combined 2025 neurointerventional revenue was ~RMB 2.3 billion, implying a combined share of ~18%–23% against a RMB 10–13 billion market (this report's estimate); a unified-basis CR3/CR5 was not available. Entry barriers: Class III registration certificates + 3–5 years of clinical trials, precision nitinol processing, operator training and clinical trust (Chairman Zhao Zhong candidly acknowledged that "physicians' confidence in domestic devices" remains a hurdle), and VBP qualification thresholds. Substitution threats: surgical clipping/IV thrombolysis/drug therapy; interventional procedures continue to substitute for open surgery — a direction favorable to the industry.
Cycles and Regulation: The industry is in "early-to-mid growth + post-VBP cycle" — coil VBP began with Hebei's first procurement in 2021 (average reduction 46.8%), followed by the 2023 21-province alliance (64.1% reduction), and 2024–2025 national alliance + national procurement (Gansu-led 24-province alliance for 5 peripheral categories, 62.2% reduction; fifth national procurement batch for peripheral stents implemented 2025-05; sixth batch covering DCB + urology opening bids 2026-01); leading domestic players collectively turned profitable in 2023–2024, with profit realization expected in 2025–2026; peripheral VBP implementation slightly lags neurointervention. Key regulatory points: ① In 2026, the National Healthcare Security Administration confirmed at least one more national procurement batch (the seventh batch opens bids 2026-09 for digestive interventional products — neurointervention not included; the eighth batch candidate pool is open); ② "anti-involution / no volume commitment for unreasonably low prices" has become the 2025–2026 VBP rule orientation (reflected in the seventh batch), but is not a commitment against scope expansion; ③ healthcare anti-corruption became normalized in 2024–2025, with the impact already dissipated; ④ DRG/DIP national full coverage from 2025 — consumables account for over 80% of neurointerventional procedure costs, and payment constraints favor cost-effective domestic products; ⑤ innovation support: the company gained 4 new innovation designations in 2025, with 61 NMPA approvals cumulative; the innovative device special review channel accelerates registration.
Company's Industry Position (side-by-side bases): ① Total company revenue basis — 2025 revenue of RMB 1.057 billion ranks first among listed domestic neurointerventional companies (MicroPort NeuroScience RMB 790 million, Peijia RMB 713 million, Shingwei RMB 408 million); ② pure neurointerventional segment basis — 2025 neuro revenue of RMB 676 million still ranks second domestically behind MicroPort NeuroScience's RMB 790 million. In short, "first overall, second in neurointervention," and the only "neuro + peripheral" dual-platform company in the domestic camp (Dongxing Securities citing Frost & Sullivan: Zhongchuang is the only domestic company covering all three categories in neurovascular intervention — ischemic/hemorrhagic/access). Share trend is rising: turnaround to profit in 2024, 2025 profit +143.7%, hospital coverage 3,000→3,500, overseas presence in 70 countries with 94 products. Marginal changes in competitive dynamics: Shingwei's 2026H1 revenue +56.9% poses share pressure in the ischemic line; MicroPort NeuroScience's trading halt since 2026-09-01 (failure to disclose interim results on time) — suppressed promotion during the halt is a phased positive for this company, but a post-resumption rebound is a variable; Medtronic's USD 550 million acquisition of Scientia Vascular doubles down on thrombectomy, so long-term pressure from multinational giants persists.
Generic financial frameworks tend to miss three defining dimensions of the interventional device business; this report tracks them separately:
1. VBP Catalog Cycle (the price anchor). The price curve of high-value consumables is determined by the VBP catalog cadence: product lifecycle = deep cut at first procurement (40%–65%) → moderate renewal (10%–15%, Jiangsu coil precedent) → volume growth takes over. Track three things: the coil fourth procurement-year renewal document (2026Q4–2027Q1), the eighth national procurement batch product catalog (whether thrombectomy/intracranial/flow-diverter stents are included), and volume-price data after implementation of the peripheral DCB national procurement price (RMB 1,677–6,015). The company-level leading indicator is whether group gross margin falls below 70% (lowest 71.6% in FY2024 under VBP impact).
2. Registration Pipeline (the supply anchor). Class III certificate approvals are binary events that determine the revenue mix over the next 2–3 years: options in hand = liquid embolic agent (originally 2026, slipped to 2027+), drug-eluting self-expanding intracranial stent (2027, racing MicroPort NeuroScience's sirolimus-eluting stent through the innovation channel), OCT atherectomy series (2027, licensed from Avinger, filling a domestic gap), and intracranial OCT system. Historical base for the company's approval cadence: 39 commercialized products in China (FY2023) → 47 (FY2024) → 61 (FY2025) → 70 (2026H1). Pipeline delay record suggests: apply a default 6–12 month haircut to the company's pipeline timetable; read the 2026H1 R&D expense -12.5% together with the delays, and verify investment intensity in the annual report.
3. Hospital Penetration and Operator Network (the volume anchor). Hospital coverage 3,000+ (FY2023) → 3,500+ (2026H1), devices in clinical use 800,000→1.35 million — hospital count × per-hospital output is the volume decomposition; VBP wins driving hospital onboarding acceleration (DCB volume up 3.5x, Yinshe (SilverSnake) up 2.5x) has been validated twice. Overseas penetration: 70 countries / 94 products + Optimed direct sales in Europe (Germany completed, France in progress), overseas revenue share 4.6%→11.2%.
Overall Verdict: Cautiously bullish, confidence 0.58, 12–18 months. Zhongchuang-Tongqiao's quality (dual engines + 73% gross margin + 34% net cash + operating ROIC ~21%) ranks in the top tier of the domestic device camp; at the current price of HKD 20.5 it trades at 14.8–16.0x 2026E adjusted P/E, with the EPV zero-growth layer alone covering ~91% of the current price and net cash of ~HKD 7.0 per share forming a floor — downside is protected, and the upside earns the repricing of "the growth option from 9%." Confidence is anchored at 0.58 rather than higher for three reasons: valuation recovery depends on catalysts (VBP renewals, annual report, index events) with uncontrollable timing; 2026H2 is the first concentrated execution period of three VBP policies, not covered by H1 data; and low liquidity — average daily turnover is about 0.1% of market cap — means the discount could persist, and even if fundamentals deliver, price discovery may lag.
Strategic Implications: The current price sits between the bear-case upper bound and the base-case lower bound; the odds structure suits phased position building rather than a one-time bet. On a rise to HKD 30 (base-case upper bound), the margin of safety is exhausted — reassess rather than add on inertia; below HKD 17 (under the bear-case upper bound), revisit the VBP assumptions.
Risk and Catalyst Calendar: Core risks by severity — neurointerventional stents entering the eighth national procurement batch (falsification line), coil renewal cuts exceeding 25%, 2026 full-year adjusted net profit below RMB 360 million, receivables aging deterioration, Optimed goodwill impairment. Catalysts by timing — coil renewal document 2026Q4–2027Q1, profit alert window 2027-01, annual report 2027-03, liquid embolic approval, continued buybacks. Liquidity risk warning: the company's average daily turnover is about 0.08%–0.15% of market cap; institutional position building/exit entails weeks-long impact costs — position management must be constrained by liquidity.
Data sources: company 2026 interim results announcement (2026-08-20), 2026 interim report (2026-09-22), FY2025/FY2024 annual results announcements, September 2026 monthly return of movements in securities; NHSA and provincial healthcare security administration VBP documents; CIC / Frost & Sullivan (prospectuses and sell-side citations); sell-side consensus (Investing.com/StockAnalysis, retrieved 2026-10-10). Price anchor: closing price of HKD 20.50 on 2026-10-09.